Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery

NCT ID: NCT04153383

Last Updated: 2023-09-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-30

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to analyze the changes in cardiac performance before and after milrinone administration in order to find out whether milrinone improves LV performance in patients undergoing coronary artery bypass surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TMAD

Tissue motion annular displacement (TMAD) of tricuspid valve annulus transesophageal echocardiography

Milrinone Injection

Intervention Type DRUG

giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/min IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Milrinone Injection

giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/min IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Milrinone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient agree and provide written informed consent.
* patient undergoing elective coronary artery bypass graft surgery
* preoperative LV EF\>50% (TTE)

Exclusion Criteria

* preoperative cardiac dysrhythmia
* preoperative IABP
* use of other inotropic agents
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Konkuk University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tae-Yop Kim, MD PhD

Professor of Anesthesiology

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KUH0000000123

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of Sivelestat Sodium in OPCABG
NCT07118930 RECRUITING PHASE2
Protection During Cardiac Surgery.
NCT03230136 COMPLETED NA
Unstable Angina Pectoris Trial
NCT00000486 COMPLETED PHASE3
Feasibility of Transepicardial Atrial Injection
NCT05634213 WITHDRAWN EARLY_PHASE1
Amino Acid Infusion in Cardiac Surgery
NCT07030933 NOT_YET_RECRUITING PHASE4
Microcirculation in Cardiac Surgery
NCT01330745 COMPLETED NA